Avoid Mishaps With SGLT2 Inhibitors
September 2022
More inpatients will get SGLT2 inhibitors...canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin.
These meds were originally approved for type 2 diabetes. But now they’re also recommended for certain patients with heart failure.
Avoid mishaps with SGLT2 inhibitors as use increases.Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote